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Abstract
Background
Referral to specialized palliative care services (SPCS) occurs often late in the illness trajec-
tory but may differ across cancer types. We examined differences between cancer types in
the use and timing of referral to specialized palliative care services (SPCS) and in the rea-
sons for non-referral.
Methods
We conducted a population-based mortality follow-back survey among physicians who certi-
fied a representative sample of deaths in Flanders, Belgium. We focused only on sampled
death cases of cancer (n = 2392). The questionnaire asked about the use of the existing
types of SPCS and the timing of referral to these services.
Results
Response rate was 58% (1394/2392). Patients who died from breast, respiratory, head and
neck, genitourinary or gastrointestinal cancer had higher chances of using SPCS compared
to hematologic cancer patients. The most prevalent reason for non-referral was that regular
care sufficiently addressed palliative and supportive care needs (51%). This differed signifi-
cantly between cancer types ranging from 77,8% for breast cancer and 42.1% for hemato-
logic cancer. A second prevalent reason for not using SPCS was that it was not meaningful
(enough) (23.9%), particularly for hematologic malignancies (35,1%) and only in 5.3% for
breast cancer.
Conclusion
Differences in referral across different types of cancer were found. Referral is more often
delayed or not initiated for patients with hematologic cancer, possibly due to differences in
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illness trajectory. An influencing reason is that physicians perceive palliative care as not
meaningful or not meaningful enough for these patients which may be linked to the uncer-
tainty in the disease trajectory of hematologic malignancies.
Introduction
Cancer patients often suffer from various disease- or treatment-related symptoms that may
result in high symptom burden, physical, emotional and spiritual suffering, which reduces
quality of life [1,2]. Quality of life is increasingly recognized as an important outcome for can-
cer patients and studies have demonstrated that it is positively influenced by the early integra-
tion of specialized palliative care services (SPCS) in standard oncology care [3–6]. The
definition of palliative care (PC) of the World Health Organization (WHO) also states that it
should be integrated early in the disease trajectory of patients suffering from life-limiting ill-
nesses alongside disease modifying therapies [7]. Not every patient requires specialized pallia-
tive care since palliative care needs may be met by physicians with basic palliative care skills
but in cases of complex palliative care problems, referral to specialized palliative care services
(SPCS) is needed [8–10]. Advanced cancer is often associated with high and complex symptom
burden but research shows low referral to specialized palliative care programs in oncology care
[11]. In addition, SPCS are traditionally still initiated very close to death and not early in the
disease trajectory [12–14].
Previous research of use and timing of SPCS showed that cancer patients were referred late
(median: 16 days before death) in the disease trajectory but perceived cancer patients as a
homogeneous group and did not examine differences in referral between cancer types [12,14].
However, different cancer types have distinct symptom clusters and illness trajectories, and
physicians have reported that these aspects influenced their past decisions to refer to SPCS
[15–19]. In addition, also non patient-related characteristics such as physician and staff’s
knowledge about palliative care and SPCS influences referral practices, practice specialty even
influences patient’s survival after referral to SPCS [18]. This suggests that differences in referral
and timing of referral might exist between oncology subspecialties and hence cancer types
[20].
Some studies looked at the availability of SPCS for patients in cancer types and reported sig-
nificant differences between cancer types in timing of referral to palliative care [21,22]. How-
ever, this evidence is limited to data at an institutional level, not at population level.
Information is needed at a population level in order to assess the actual integration of palliative
care in oncology care across care settings.
The aim of this population-based retrospective study is to examine whether there are differ-
ences between cancer types in the use of SPCS, in the type of service used in particular in the
timing of referral to SPCS, and in the reasons for non-referral.
Methods
Death certificate study
We conducted a population-based survey, based on a large and representative sample of death
certificates in Flanders, Belgium. The Flemish Agency for Care and Health, the central admin-
istration authority for processing death certificates, selected a random sample of deaths in the
first half of 2013. For this analysis, we focus only on sampled death cases of malignant cancer
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(ICD-10 C00-C97). One third of all cancer deaths of Belgian residents aged one year or older
were sampled from January 1st until June 30th 2013. This resulted in a sample of 2,669 cancer
related-deaths.
Within two months of the death, every physician certifying a death certificate in the sample
received a questionnaire about the end-of-life care and decision making regarding this case.
The physicians were requested to complete the questionnaire consulting the patient’s medical
file. If the certifying physician was not the treating physician, the questionnaire was to be
passed on to the treating physician. A one-page questionnaire was mailed to all non-respond-
ing physicians, inquiring about reasons for not participating.
Questionnaire
The questionnaire about end-of-life care and decision making has been repeatedly used in ear-
lier studies [23–25], the questions regarding palliative care referral, which were tested by a
panel of 10 physicians via cognitive interviews to correct for ambiguities, were added to the
questionnaire. The questionnaire first asked whether death had been sudden and totally unex-
pected. If answered negatively–and hence referral to specialised palliative care services could
not be precluded–physicians were asked whether and when they had: (1) initiated specialized
palliative care services, (2) what the treatment goal was in the last week of life and (3) what the
reasons were for not using SPCS.
1. Use of specialised palliative care services. The physician was asked if one or more of the exist-
ing types of SPCS in Belgium had been involved in the care of the deceased patient. These
services are: multidisciplinary palliative home care teams (team skilled in palliative care
who care for the patient and support the caregivers at home), mobile hospital-based pallia-
tive care teams (multidisciplinary team that guides palliative care in the different wards of
the hospital), inpatient palliative care units (separate wards in the hospital with a multidisci-
plinary team delivering palliative care) and a palliative care reference person in a nursing
home (usually a nurse) trained in and responsible for palliative care. The physician was also
asked to indicate the timing of the referral, i.e. the number of days between the first referral
to a SPCS and death.
2. Treatment goal in the last week of life. The physician was asked to indicate the main treat-
ment goal in the last week of life, the possibilities were life prolongation/curation or com-
fort/palliation.
3. Reasons for not using palliative care services. When none of the SPCS been involved in the
end-of-life care of the patient, physicians could mark the reasons why no such services were
used: 1) palliative care was not meaningful or not meaningful enough (not relevant, i.e. not
of value), 2) palliative care was not available, 3) existing care already sufficiently addressed
the patient’s palliative and supportive needs, 4) there was not enough time to initiate pallia-
tive care, 5) in order not to deprive the patient and/or family of hope, 6) the patient did not
want it, 7) the family did not want it or 8) another reason (with the request to specify the
reason in text). The reasons in this category were afterwards checked by the researchers and
allocated to one of the previous categories where possible. Physicians could tick more than
one reason for each patient. The possible reasons were selected based on relevant literature
about factors hindering the use of palliative care services [17,18,26–29] and on preceding
qualitative research on reasons for not using palliative care [30].
Demographic and clinical patient data were obtained from the death certificate and linked
anonymously after data collection.
Use of specialized palliative care in oncology
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Analysis
The response sample was corrected to be representative of all cancer deaths in the first half of
2013 in terms of age, sex, marital status, province of death, cause of death and place of death
(adjustments only needed for place of death). After this weighting procedure there were no sig-
nificant differences between response sample and all deaths on any of these variables. Due to
the format of the questionnaire, only non-sudden deaths were considered. All analyses were
based on complete cases. Pearson chi square tests analyses were performed for patient and
treatment characteristics according to cancer types. For referral to SPCS and reasons for not
referring to SPCS non-sudden deaths were considered due to the format of the questionnaire.
We also performed a multivariable logistic regression to look at differences between cancer
types in SPCS referral and to explore characteristics of cancer patients that are independently
related to the use of specialised palliative care services. The non-parametric Kruskal-Wallis test
was calculated to test for differences in timing of referral between cancer types. All calculations
were made using the in SPSS version 23.0 (SPSS, Inc., Chicago, IL).
Anonymity and ethical considerations
To guarantee absolute anonymity for participating physicians, a lawyer served as an intermedi-
ary between responding physicians, researchers and the Flemish Agency for Care and Health,
ensuring that completed questionnaires could never be linked to a particular patient or physi-
cian. After data collection a one-page questionnaire was mailed to all non-responding physi-
cians, inquiring about reasons for not participating. The study was approved by the Ethical
Review Board of the University Hospital of the Vrije Universiteit Brussel, the Belgian National
Disciplinary Board of Physicians, and the Belgian Privacy Commission.
Results
Questionnaires were returned for 1,394 of 2,669 cancer deaths. Non-response questionnaires
revealed that responding was impossible in 277 cases, for example because the physician did
not have access to the medical file or the patient could not be identified. Therefore, the
response rate was 58.3% (1,394 of 2,392 cases).
Case characteristics
Patients dying from different cancer types (breast, respiratory, gastrointestinal, genitourinary,
head and neck, hematologic or other cancers) differed significantly in terms of distribution for
sex, age, living situation and marital status (Table 1).
Use of specialized palliative care services
The use of specialized palliative care services differed between cancer types (p = 0.007). People
who died from head and neck cancer used specialized palliative care services the most (86.3%),
in all other cancer patients over 73% get access to SPCS, except for people who died from
hematologic cancer with 56.4%.
The median timing of referral before death was highest in breast cancer patients (29 days)
and lowest in hematologic cancer patients (10 days) (Fig 1). Fig 1 shows an important variation
in timing of referral to specialized palliative care services in the groups of patients who died
from breast cancer, respiratory cancer or head and neck cancer, while for gastrointestinal, gen-
itourinary and hematologic cancer this within-group variation was less. However, these differ-
ences between cancer types were not statistically significant (Table 2). The treatment goal in
the last week of life differed between cancer types (p => 0.044). However, considering
Use of specialized palliative care in oncology
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multiple testing, the evidence of differences between cancer types is not strong enough to
make any clear conclusions.
Characteristics associated with using specialized palliative care services
When comparing the use of palliative care services between solid cancer types and hematologic
cancer in multivariable logistic regression, and after bringing socio-demographic characteris-
tics into consideration, patients who died from breast, gastrointestinal, respiratory, head and
neck, genitourinary cancer and patients dying from other cancers had higher odds of using
specialized palliative care services compared to patients dying from hematologic cancer
(Table 3).
Table 1. Patient characteristics of all non-sudden cancer deaths according to cancer types (in percentages).
All cancer deaths
(n = 1079)
Breast
(n = 90)
Gastrointestinal
(n = 317)
Respiratory
(n = 266)
Genitourinary
(n = 187)
Head and Neck
(n = 31)
Hematologic
(n = 89)
Other�
(n = 98)
p-value†
Sex <0.001
Male 57.6 0 59.9 71.1 58.8 77.4 64.0 51.5
Female 42.4 100 40.1 28.9 41.2 22.6 36.0 48.5
Age at death <0.001
1-64y 25.1 34.4 21.4 31.1 10.7 58.1 18.2 36.1
65-79y 41.3 41.1 43.1 46.8 43.9 29.0 29.5 29.9
� 80y 33.6 24.4 35.5 22.1 45.5 12.9 52.3 34.0
Place of death 0.057
Hospital (excl. PCU) 40.5 33.0 40.0 44.3 37.5 35.5 51.7 35.7
PCU 13.2 22.0 12.4 12.5 12.5 16.1 10.1 13.3
Home 34.9 28.6 36.2 37.5 34.2 41.9 25.8 36.7
Care Home 10.7 16.5 10.5 5.7 14.1 6.5 12.4 13.3
Other 0.7 0.0 1.0 0.0 1.6 0.0 0.0 1.0
Living Situation 0.039
Alone 21.5 20.2 18.5 19.7 26.1 25.8 29.2 19.6
In household with others 67.5 62.9 72.7 72.7 60.3 64.5 55.1 68.0
Institution 11.1 16.9 9.3 7.6 13.6 9.7 15.7 12.4
Marital status <0.001
Unmarried 7.1 3.3 7.6 6.8 4.3 16.7 10.0 10.2
Married 57.3 52.2 59.3 62.4 58.3 53.3 45.6 52.0
Widowed 26.0 37.8 26.2 16.2 28.9 13.3 38.9 27.6
Divorced 9.5 6.7 6.9 14.3 8.6 16.7 5.6 10.2
Other 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0
Attending physician 0.017
Hospital specialist 50.0 50.0 47.8 53.9 47.1 38.7 59.6 47.4
Family physician 46.6 50.0 46.8 43.8 49.7 48.4 39.3 50.5
Other 3.3 0.0 5.4 2.2 3.2 12.9 1.1 2.1
Percentages are column percentages.
†Pearson χ2 test testing for differences between the types of cancer: breast, respiratory, colorectal, genitourinary and other.
� Other: bone & articular cartilage -, skin-, eye; brain & central nervous system-, thyroid & endocrine glands-, ill-defined; secondary and unspecified sites and
independent multiple sites. Only non-sudden deaths are reported since physicians were not asked to answer questions related to referral to specialist palliative care
services when death had occurred suddenly and totally unexpectedly.
https://doi.org/10.1371/journal.pone.0210056.t001
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The test of model effects was significant (p = 0.02) indicating that our model has a signifi-
cant model estimation fit. Cox & Snell R Square (0.032) and Nagelkerke R Square (0.047) indi-
cate that our model has modest predictive power.
Reasons for not using palliative care services
Of the 19% (n = 268) of cancer patients who were not referred to SPCS, the physician per-
ceived the regular care as sufficiently addressing the patient’s palliative and supportive needs
in 51% of the cases (Table 4). This differed significantly between cancer types, ranging from
77.8% in breast cancer (77,8%) to 42.1% in hematologic cancers (42.1%), without taking head
and neck cancers into account (n = 3). Only 4.6% of patients who died of breast cancer did
receive neither palliative care nor regular care which, according to the physician, sufficiently
met palliative and supportive care needs. This ranged between 15.1% to 8.7% for all other solid
cancer types. Patients with hematologic cancer had the highest percentage (25.2%) (Not shown
in table).
Another prevalent reason, differing significantly between cancer types, was that palliative
care was not meaningful or not meaningful enough according to the physician (23.9%),
Fig 1. Box plot of timing of referral to palliative care services (days before death) per cancer type. Outliers are not
shown and differ per cancer type: Breast:> 114 days (n = 7); Gastrointestinal:> 64 days (n = 26); Respiratory:>107
days (n = 11); Genitourinary:> 60 days (n = 14); Head &Neck:>107 days (n = 1); Hematologic:> 65 days (n = 5);
Other:> 105 (n = 5).
https://doi.org/10.1371/journal.pone.0210056.g001
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Table 2. Rates, timing of referral to specialist palliative care services and treatment goal in the last week of life; % of non-sudden deaths.
All cancer
deaths
(n = 1079)
Breast
(n = 90)
Gastro-
intestinal
(n = 317)
Respiratory
(n = 266)
Genitourinary
(n = 187)
Head and
Neck
(n = 31)
Hematologic
(n = 89)
Other
(n = 98)
p-value
Any type of PC† 74.2 79.5 73.1 75.9 75.6 86.3 56.4 78.4 0.007
Palliative care support at home 30.8 30.9 29.3 35.1 27.8 43.8 20.2 35.1 0.076
Hospital-based palliative care service
(excl. Palliative care unit)
32.1 32.2 32.5 36.3 31.3 37.2 27.7 23.5 0.503
Palliative care unit 15.3 19.7 15.8 14.0 15.2 23.8 12.8 15.0 0.805
Palliative care reference person in a
nursing home
3.6 13.7 5.7 1.6 9.0 5.0 3.5 9.5 <0.001
Other 3.1 3.5 3.4 2.6 5.6 0.0 0.0 1.8 0.172
Median days prior to death�‡ 16 29 14 19 20 14 10 21 0.173
P25 & P75 7; 33 10;52 7; 30 7; 47 10;30 4; 45 3; 28 10; 48
Mean 37 44 35 39 36 37 31 35
Treatment goal in the last week 0.044
Life prolongation/curation 30.3 25.2 33.4 26.4 29.2 23.1 41.1 30.2
Comfort/palliation 69.7 74.8 66.6 73.6 70.8 76.9 58.9 69.8
Percentages are column percentages. Percentages may add up to more than the total percentage of referrals because more than one palliative care service was used in
some cases.
�Calculations for only patients with a referral to palliative care services, n = 792. Missing values 12.8% (n = 101)
†Pearson χ2 test testing for differences in referral between the seven different cancer types.
‡Kruskal-Wallis test testing for differences in time of onset between the seven cancer types, minimum 1, maximum 666
https://doi.org/10.1371/journal.pone.0210056.t002
Table 3. Multivariabele odds ratios and probabilities for referral to specialist palliative care services, according to
type of cancer and sociodemographic characteristics for all non-sudden cancer deaths.
Using SPCS�
OR (95% CI)
multivariate
Model-estimated
Probabilities
(%)
Type of Cancer
Breast 2.25 (1.06–4.80) 0.76 (0.64–0.85)
Gastrointestinal 2.00 (1.17–3.44) 0.74(0.68–0.79))
Respiratory 2.29 (1.31–4.02) 0.74 (0.68–0.80)
Genitourinary 2.28 (1.25–4.15) 0.75 (0.67–0.81)
Head & Neck 4.58 (1.34–15.65) 0.87 (0.70–0.95)
Hematologic Ref Cat 0.59 (0.47–0.69)
Other 2.60 (1.28–5.27) 0.81 (0.71–0.88)
Living situation
Alone 1.22 (0.80–1.85) 0.79 (0.73–0.85)
In household with other Ref Cat 0.77 (0.72–0.81)
Institution 0.72 (0.46–1.11) 0.71 (0.62–0.79)
Age
18-64y 1.32 (0.86–2.04) 0.78 (0.71–0.83)
65–79 y 1.46 (1.01–2.10) 0.79 (0.74–0.84)
� 80 y Ref Cat 0.70 (0.64–0.75)
Sex
Male Ref Cat 0.73 (0.67–0.78)
Female 1.42 (1.01–1.99) 0.78 (0.73–0.83)
https://doi.org/10.1371/journal.pone.0210056.t003
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particularly in hematologic cancer (35.1%). Interestingly, this reason was only mentioned in
5.3% of breast cancer patients. According to the physicians, not having enough time to refer
the patient to palliative care services also occurred frequently (26.4%) but this did not differ
significantly between cancer types. In some cases (12.7%) patients refused to be referred to spe-
cialized palliative care services which differed significantly between cancer types.
Discussion
Our study found that an important proportion of Flemish cancer patients were referred to spe-
cialized palliative care services prior to death, varying from 56% for hematologic cancer to
75% for breast cancer. However, referral mostly occurred late in the disease trajectory and
chances for referral are not equal for patients dying from various cancer types. Patients with
hematologic cancer have smaller chances of referral to any SPCS compared to all other solid
cancers, even after controlling for patient characteristics. Reasons for non-referral to SPCS
also differed significantly between cancer types. The most indicated reasons were that 1) stan-
dard care already sufficiently addressed the patient’s palliative care needs, 2) there was not
enough time and that 3) palliative care was not meaningful or not meaningful enough.
This study has several strengths. This population-based study constitutes a large representa-
tive sample of cancer deaths in Flanders and has an appropriate design to evaluate the referral
or non-referral to specialized palliative care services of deceased cancer patients. This study is
not limited with regard to care setting or sample size. Furthermore, because of the nationwide
scope of this study, our results allow for international comparative research. A shortcoming of
this study is the one- to two-month interval between death of the patient and the sending of
the questionnaire which might result in recall bias for some cases [24,31,32]. Additionally,
treating physicians might not always have knowledge about the specific palliative care services
provided across different setting of care (e.g. community versus hospital) resulting in a possi-
ble underestimation of the use of specific specialized palliative care services. We also did not
exclude patients under the age of 18 who may have different care compared to adults. How-
ever, we believe this to have little influence on our findings due to the small N of child and
Table 4. Reasons given by physicians for not using specialist palliative care services (PCS) in patients who died of cancer.
Care sufficient
(%)
Not meaningful
(%)
Not enough time
(%)
Patient did not want
(%)
Family did not want
(%)
Not available
(%)
Not take away hope
(%)
All cancer types (n = 268) 51.3 23.9 26.4 12.7 5.2 1.1 0.7
Cancer type
Breast (n = 19) 77.8 5.3 16.7 10.5 0.0 0.0 0.0
Gastrointestinal (n = 83) 44.0 25.3 27.7 15.7 3.6 2.4 0.0
Respiratory (n = 62) 52.4 22.6 23.8 15.6 11.1 0.0 1.6
Genitourinary (n = 45) 64.3 13.3 21.4 4.8 7.0 2.3 2.2
Head and Neck (n = 3) 0.0 33.3 0.0 66.7 0.0 0.0 0.0
Hematologic(n = 37) 42.1 35.1 32.4 10.5 0.0 0.0 0.0
Other (n = 19) 52.6 42.1 42.1 5.3 5.0 0.0 0.0
Full response answers which physicians could indicate as a reason for not using palliative care services were respectively: the care already sufficiently addressed the
patient’s palliative and supportive needs; palliative care was not meaningful or not meaningful enough; there was not enough time to initiate palliative care; patient did
not want it; family did not want it; palliative care was not available; to not take away the hope of the patient and/or the family.
Abbreviations: PCS = palliative care services.
Percentages are row percentages. Percentages may add up to more than 100 because more than one reason could be indicated in some cases.
�Bivariate Pearson χ2 test testing for differences in between cancer types. Bold denotes significant at p < .05.
https://doi.org/10.1371/journal.pone.0210056.t004
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adolescent deaths in our sample. Further, the questionnaire is necessarily (such as all surveys)
a reduction of reality and cannot capture all the nuances of care. Our study also focuses only
on formal care of SPCS, the palliative care approach provided by other health care provisional
is neglected. Further, we did not correct for multiple testing in our analysis and due to width
of the 95% confidence interval and the small sample size of the head & neck patients in our
study, no clear conclusion can be drawn for this group of patients regarding the odd of referral
to SPCS, compared to hematology patients. Last, the reasons for not using palliative care only
include aspects related to treatment options and are based on the physician’s perspectives. Per-
spectives of patients, carers and other professional caregivers is missing.
Our findings show that SPCS are widely available for cancer patients in Belgium which is
similar to other countries such as Canada and Australia[33,34], In addition, most of the cancer
patients in this study were either referred to one or more of the different services before death
or received regular care which sufficiently supported the palliative care needs according to the
physician. These are reassuring results indicating that a palliative care approach is not
neglected in oncology care and concur with the palliative care model in Belgium which is very
much based on specialized palliative care provided by specialized palliative care professionals
and less on a generalist palliative care approach [35].
The idea of palliative care integrated early in cancer care has gained momentum in recent
years[36], yet in day-to-day practice in Belgium specialized services are only involved in the
final days of life especially compared to other countries. In our study timing of referral to
SPCS did not differ significantly between cancer types, but was the longest for breast cancer
patients (median of 29 days) and the shortest for patients with hematologic cancers (median of
10 days). This is late compared to other countries such as the United Kingdom (UK) where
patients with breast cancer and patients with hematologic cancer were referred 43.5 and 26
days prior to death respectively[37]. In addition, institutional data shows that in the United
States, and in Australia cancer patients were referred, respectively 42 days and 54 days prior to
death [21,38]. The Belgian health care system is likely to have an impact on our findings since
the current reimbursement and eligibility criteria to be granted a “palliative status’, which cov-
ers the costs of additional medicines and materials through health insurance, is that patients
are expected to live three months or less. This might strengthen the idea of palliative care as
terminal care. This late referral is an important concern since the end-of-life care in Belgium is
more hospital centric with high chemotherapy utilization, compared to other countries such as
the United States [39]. This raises the important issue whether palliative care professionals in
Belgium have enough time to establish comfort care for cancer patients at the end-of-life.
The found discrepancies in use of specialized PC services between hematologic cancer
(54%) and solid cancer types (78%) concur with findings from the UK (12% versus 28%) and
Canada (25% versus 36%) [40]. An important finding of our study was that 25% of patients
suffering from hematologic cancer were not referred to SPCS or did, according to the physi-
cian, not receive usual care that sufficiently addressed the palliative care needs while this is
only the case for 5% of patients who died of breast cancer and about 12% for patients who died
from all other types of cancer. Several reasons might be related to the discrepancies. One sug-
gested reason is that patients suffering from advanced cancer of solid tumors experience
higher, more complex and more diverse symptom burden and thus clearer indications of the
need for referral to SPCS [21,41]. Another reason is that the illness trajectory for hematologic
cancer is less predictable. Hematologic cancer is often characterized by acute exacerbations of
the illness followed by highly technical therapies that can continue over many years. This,
along with a rapid dying trajectory, results in difficulties in assessing the right time to refer to
SPCS [19,42,43].
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Nonetheless, hematological cancer patients have been shown to have similar symptom con-
trol needs to other cancer patients in all phases of the disease and evidence suggests that hema-
tologic cancer patients have similar patterns of physical decline at the end of life [22, 44–46]
This suggests that other factors than clinical and treatment characteristics might also play a
role in referral to SPCS. Organizational aspects might influence referral practices since transfu-
sion of blood products might benefit the quality of life of hematologic cancer patients but is
often impossible in a palliative setting [47] Also intrapersonal aspects, such as attitudes and
perceptions of patients, family and medical staff toward PC may affect referral to SPCS. Inter-
estingly, we found that physicians frequently perceive palliative care as not meaningful or not
meaningful enough, particularly so for patients who died from hematologic cancer. Possible
hypotheses for these findings might be that Belgian hematologic oncologists, compared to
solid tumor oncologists, more frequently perceive palliative care as end-of-life care and per-
haps also as antithetical to cancer care [48]. Research shows that hematologists often view
treatment goals or disease characteristics in hematology care as incompatible with palliative
care [49–52]. On the other hand, it is also plausible that hematologists consider the delivery of
palliative care to be integral to their role, hematologists might be concerned that referral to
SPCS may alarm the patient and family caregiver[53,54]. Research has reported that the close
relationship developed between hematologists and their patients during the treatment course
might be a barrier for collaboration between both disciplines[55].
Our results also point out that palliative care is very well integrated in the usual care for
breast cancer patients since 95% of patients who died of breast cancer were referred to SPCS
or received usual care that sufficiently addressed the palliative care needs according to the phy-
sicians. The mechanism behind these differing results related to cancer type remain unclear.
For breast cancer, for example, psychosocial interventions influencing quality of life are well
integrated in the regular care which might lead to higher awareness of the benefits of palliative
care among professional health carers and patients, resulting in earlier referral to palliative
care [56]. Similarly, research shows that the dichotomized thinking of some hematologists,
with the “either/or” approach to active treatment and palliative care may act as a barrier for
collaboration with SPC[55]. This might influence patients and families who as a result under-
estimate the benefits of palliative care and continue to perceive palliative care as terminal care
only. Evidence shows that bereaved family members of patients with hematologic cancer felt
unprepared for the dying experience and felt unsupported to deal with spiritual pain. This evi-
dence supports the missed opportunity of the benefit of a palliative care approach [44,54].
Conclusion
Despite increasing evidence of the benefit of early integration of palliative care for cancer
patients, our study contributes to the awareness that the use of palliative care services in Bel-
gium is high but still occurs late in the disease trajectory. Palliative care is still perceived as ter-
minal care which may lead to unmet palliative care needs of cancer patients and their families,
particularly in hematologic malignancy. For these and other cancer patients, further research
is needed to test the beneficial effects of early integration of palliative care in oncology care.
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